Merck's Lipfendra: A Groundbreaking Oral Cholesterol Medication Approved by FDA
Significant Advancement in Cardiovascular Treatment
In a significant development for cardiovascular health, Merck announced on Thursday that the US Food and Drug Administration (FDA) has granted approval for its oral cholesterol medication, Lipfendra (enlicitide). This marks a historic moment as it becomes the first oral drug of its kind to receive regulatory approval. This move is part of Merck's strategy to broaden its product range beyond Keytruda, its leading cancer treatment, which is expected to face patent expiration and competition from lower-cost biosimilars starting in 2028.
Key Information About Lipfendra
Lipfendra is indicated as a supplement to diet and exercise for lowering LDL cholesterol, often referred to as 'bad' cholesterol, which contributes to arterial plaque formation. It is suitable for adults suffering from hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), as stated in Merck's announcement. This innovative macrocyclic peptide works by binding to PCSK9, inhibiting its interaction with LDL receptors, making it the first oral PCSK9 inhibitor approved by the FDA.
Previously, the PCSK9-inhibitor market was primarily occupied by injectable medications, such as Amgen's Repatha and the Regeneron-Sanofi product Praluent. The introduction of a once-daily pill presents a more user-friendly option for patients who have relied on regular injections.
The FDA's approval followed successful Phase 3 trials, namely CORALreef Lipids and CORALreef HeFH. Results indicated that after 24 weeks, Lipfendra reduced LDL cholesterol by 56% in the Lipids trial and 59% in the HeFH trial, along with lowering other cardiovascular risk markers like non-HDL cholesterol and apolipoprotein B. Safety data showed that adverse reactions were comparable between Lipfendra and placebo groups, although diarrhea (7% vs. 2% on placebo) and dizziness (9% vs. 4%) were reported more frequently with the drug in the HeFH trial.
Dean Y. Li, president of Merck Research Laboratories, described the approval as a 'pivotal moment,' emphasizing that Lipfendra was designed to merge the efficacy of PCSK9 inhibition with the convenience of a daily tablet.
Merck has announced that Lipfendra will be priced at $10.50 per day for a complete month's supply, according to reports. The medication has demonstrated significant LDL reductions in patients already taking statins, targeting a demographic that often finds it challenging to meet newer, more stringent cholesterol goals. Additionally, the drug has been awarded a National Priority Voucher by the FDA, aimed at expediting the review process for medications deemed essential for public health.
This approval follows updated cholesterol management guidelines released in March by the American Heart Association and the American College of Cardiology, which recommend that patients at high risk for heart attacks or strokes aim to lower their LDL levels below 70, and those at the highest risk below 55, as reported by Scientific American.